Articles By Rob Wright, Chief Editor 2011-2021
-
![Tim Wright Amir Kalali and Me CNS 2019]( "The CNS Summit — A Caring Community Of Collaborative Solution Finders")
The CNS Summit — A Caring Community Of Collaborative Solution Finders11/26/2019Chief editor Rob Wright explains what differentiates the CNS Summit from other biopharmaceutical industry conferences.
-
![Rob Wright with Fred Hassan Mar 2017]( "Making A Difference For Veterans: A Biopharma Bright Spot")
Making A Difference For Veterans: A Biopharma Bright Spot11/18/2019The little known story of an immigrant couple making a $15 million difference for U.S. veterans.
-
![Rob Wright 2017]( "What's The Next Big Thing Besides China?")
What's The Next Big Thing Besides China?11/1/2019Like it or not, the U.S. and China are hugely important to one another. And while the U.S. is currently the world’s largest economy, that could soon change — and as early as next year.
-
![reputation management_450x300]( "Negative Perceptions Of Biopharma — Let's Get The Ugly On The Table")
Negative Perceptions Of Biopharma — Let's Get The Ugly On The Table11/1/2019A Life Science Leader reader shares their thoughts on why the biopharmaceutical industry’s reputation is so dismal, but also proposes solutions for how to repair it.
-
![Impact Investing_Tim Ring_450x300]( "From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan")
From Medtech CEO To Impact Investor — Not Your Typical Retirement Plan11/1/2019Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.
-
![Feature - BeiGene_John Oyler1_450x300]( "How — And Why — John Oyler Built BeiGene")
How — And Why — John Oyler Built BeiGene11/1/2019We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may surprise you.
-
![IMG_3795]( "Want To Start Fixing Biopharma's Reputation? Let's Start By Sharing More Biopharma Brightspots")
Want To Start Fixing Biopharma's Reputation? Let's Start By Sharing More Biopharma Brightspots10/10/2019With the biopharmaceutical industry’s reputation at an all-time low, Life Science Leader’s Rob Wright looks to share little-known stories of the good being done by employees of biopharma. This first installment involves Antoine Yver, M.D., EVP and global head of R&D at Daiichi Sankyo, who helped to cofound a 501(c)3 nonprofit restaurant, The Blue Bears Special Meals.
-
![Audentes_Matt_450x300]( "Building A $1 Billion Gene Therapy Company — In 6 Years")
Building A $1 Billion Gene Therapy Company — In 6 Years10/1/2019Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly $2 billion, in just seven years.
-
![Rob Wright_2017_450x300]( "It's About Time The Business Roundtable Got With The Times")
It's About Time The Business Roundtable Got With The Times10/1/2019Our Chief Editor shows how The Business Roundtable’s recent statement redefining the purpose of an American corporation can be related to our cover feature this month on Audentes Therapeutics.
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL